Millennium Development Goal 8E aims for affordable access to essential medicines. Essential medicines, as defined by WHO, are those that “satisfy the health-care needs of the majority of the population” and that should therefore “be available at all times in adequate amounts”. However, there... is a category of medicines that faces a unique challenge in terms of availability. These are the medicines governed by the international conventions on narcotic and psychotropic substances. “Controlled medicines” is the common definition for pharmaceuticals whose active principles are listed under the 1961 United Nations Single Convention on Narcotic Drugs as amended by the 1972 Protocol, such as morphine and methadone; the 1971 United Nations Convention on Psychotropic Substances, such as diazepam and buprenorphine; and the 1988 United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, such as ergometrine and ephedrine. The conventions list substances in “Schedules” according to their different levels of potential for abuse and harm, and the commensurate severity of control measures to be applied by countries.
more
Le COVID-19 est un nouveau coronavirus, proche de celui du Syndrome Respiratoire Aigu Sévère (SRAS) qui avait été à l’origine d’une épidémie meurtrière en 2003. L’infection par ce nouveau coronavirus se manifeste le plus souvent par une fièvre et des signes respiratoires pouvant se co...mpliquer par un syndrome de détresse respiratoire aiguë. Jusqu’à présent, la plupart des cas graves ont été signalés chez des personnes souffrant d’autres problèmes de santé, comme le cancer, le diabète ou une maladie rénale ; ou encore parmi des travailleurs de la santé qui sont en contact étroit avec les malades.
more
Lignes directrices provisoires, 13 août 2020
L’OMS a établi cette brève note d’information pour répondre au besoin de recommandations sur la prestation sûre de soins à domicile aux patients présumés atteints de l’infection par le nouveau coronavirus (2019-nCoV) présentant des symptô...mes bénins, et sur les mesures de santé publique liées à la prise en charge des contacts asymptomatiques.
more
El propósito de este documento es presentar orientaciones para mejorar la aplicación de medidas de salud pública no farmacológicas durante la respuesta a la COVID-19, así como la adherencia a dichas medidas por parte de los grupos de población en situación de vulnerabilidad. Para ello, es nec...esario identificar los principales obstáculos a la aplicación de las medidas, lo que nos permite determinar los grupos y territorios más afectados en las diferentes fases de la pandemia. Con este objetivo, y desde un marco de equidad, derechos humanos y diversidad, se recomiendan políticas, estrategias e intervenciones que acompañan la aplicación y flexibilización de las medidas, de modo que nadie quede atrás.
more
Background paper 8
The Independent Panel for Pandemic Preparedness and Response
May 2021
The second edition of the joint WHO, WIPO and WTO
publication “Promoting Access to Medical Technologies
and Innovation: Intersections between public health,
intellectual property and trade” (the Trilateral Study),*
published in 2020, included a special insert mappi...ng the
challenges posed by the COVID-19 pandemic in relation
to the integrated health, trade and IP policy framework set
out in the study. The Trilateral Study and the special insert
were designed to serve as background reference for policy-
makers in the widest sense – lawmakers, government
officials, delegates to international organizations, non-
governmental organizations (NGOs) and researchers
who seek a comprehensive presentation of the full range
of issues, including institutions and legal concepts with
which they may be unfamiliar. It is also designed to serve
as a factual resource for the three organizations’ technical
cooperation activities.
This update revises the information contained in that
insert in the light of more recent developments as of
30 August 2021. Further updates will be made to reflect
subsequent developments.
more
This toolkit is designed to help you plan and implement a Patient Navigation program with the best chance of reducing health disparities and improving health outcomes for your patients. It contains evidence-based and experience-based examples, case studies, practical tools, and resources to help you...:
1. Establish an evidence-based patient navigation program tailored to reduce barriers for your patients
2. Incorporate best practices to enhance current patient navigation programs or services
3. Implement a patient navigation model to address any targeted medical condition
where disparities exist
4. Hire, prepare, supervise, support and retain effective Patient Navigators
5. Navigate patients who experience health disparities
6. Evaluate patient navigation programs with the aim of continuous quality
improvement
more
Access to controlled medicines. 3rd edition